THE 9th Middle East Best of San Antonio Breast Cancer Symposium
10-11 January 2015
DAY 1
TIME
TOPICS
SPEAKER
Dr. Omalkhair Abulkhair
8:30 – 8:35
Opening Remarks
8:35 – 10:05
Breast Cancer Predisposition: Gremlins and Risk
8:35 – 9:05
Characterizing Cancer Risks for the Carrier of
Mutations BRCA1, BRCA2, PALB2 and RAD51C Genes
Dr. Antonis C. Antoniou
9:05 - 9:35
Risk Management of Hereditary Breast Cancer
Dr. Banu Arun
9:35 - 9:50
16 Year Old Long- Term Follow-up of the IBIS-I Breast
Cancer Prevention Trial
Dr. Omalkhair Abulkhair
9:50-10:05
Coffee Break
10:05- 11:30
Hormonal Therapy Update
10:05- 10:30
Biomarkers for Clinical Management and Research
ER+
Dr. Susan Fuqua
10:30- 11:00
Adjuvant Endocrine Therapy in 2015 Including Soft
Trail
Dr. Olivia Pagani
11:00 – 11:15
Fulvestrant 500mg Versus Anastrozole as First Line
Treatment for Advanced Breast Cancer: Overall
Survival from the Phase II ‘ First Study’
Dr. Ahmed Saadeddin
MODERATOR
Dr. Ezeldeen Ibrahim
Dr. Banu Arun
Dr. Heba El Zawahry
Dr. Huda Abdulkareem
Prof. Jean-Marc Nabholtz
11:15- 11:30
The FERGI Phase II Study of the PI3K Inhibitor
Pictilisib ( GDC- 0941) plus Fulvestrant plus Placebo
in Patients with ER+, Aromatase Inhibitor (AI) –
Resistant Advanced or Metastatic bBreast Cancer –
Part I Results
Dr. Mohammed Jaloudi
11:30-12:40
Triple Negative Breast Cancer Updates
11:30-11:45
The Clinical Significance of Heterogeneity in Triple
Negative Breast Cancer
Dr. Hamdy Azim
11:45-12:00
S3-01 The TNT trial: A Randomized Phase III Trial of
Carboplatin (C) Compared with Docetaxel (D) for
Patients with Metastatic or Recurrent Locally
Advanced Triple Negative or BRCA1/2 Breast Cancer
(CRUK/07/012)
Dr. Sana Al Sukhun
12:00-12:15
S4-05 . Impact of Intrinsic Subtype by PAM50 and
Other Gene Signatures on Pathologic Complete
Response (pCR) Rates in Triple-Negative Breast Cancer
(TNBC) after Neoadjuvant Chemotherapy (NACT)+/Carboplatin (Cb) or Bevacizumab (Bev): CALGB
40603/150709 (Alliance)
Dr. Shaheena Dawood
12:15-12:40
Recent Management of HER2-Triple Negative Breast
Cancer
Dr. Chris Twelves
12:40-1:40
Lunch
1:40-2:55
Update on HER2 the Breast Cancer
Dr. Shafiqah Al Awadhi
Dr. Hassan Idrisi
Dr. Jamal Al Zekeri
Dr. Nadia Mokhtar
Dr. Saleha Bajasoum
1:40 – 2:10
HER2 Positive Breast Cancer: Insights from the Lab
and Clinic
Dr. Taher Al Twigiri
2:10 -2:25
Phase 3, Randomized, Double-Blind, PlaceboControlled Multicenter Trial of Daily Everolimus plus
Weekly Trastuzumab and Paclitaxel as First-Line
Therapy in Women with HER2+ Advanced Breast
Cancer: BOLERO-1
Dr. Meteb Al Foheidi
2:25- 2:40
TBCRC023: A Randomized Multicenter Phase II
Neoadjuvant Trial of Lapatinib Plus Trastuzumab ,
with Endocrine Therapy and Without
Chemotherapy, for 12 vs. 24 Weeks in Patients with
HER2 Overexpressing Breast Cancer.
Dr. Nagi Al Saghir
2:40 - 2:55
Detrimental Effects of Sequential Compared to
Dr. Hassan Jaafar
Concurrent Treatment of Pertuzumab plus T- DM1 in
HER2+ Breast Cancer Cell Lines
2:55-3:30
Middle East Abstract
3:30-3:45
Break
3:45-4:30
Case for Discussion
- Dr. Omalkhair Abulkhair
- Naghy Al Sagir
- Dr. Amin Eltigani
Dr. Jean-Mark Nabholtz
Panelist
- Dr. Banu Arun
- Prof. Jean-Mark Nabholtz
- Dr. Mohammed AL Belwi
- Dr. Olivia Pagani
- Dr. Ezzelddin Ibrahim
- Dr. Sanaa Al Sukhun
Dr. Ahmed Saadeddin
-
Dr. Hamdi Azim
Dr. Shafiqah Al Awadhi
DAY 2
8:30-10:30
Chemotherapy Update
8:30- 8:45
9:30-10:10
S2-07. A Randomized Phase III Trial Comparing
Neoadjuvant Chemotherapy with Weekly
Nanoparticle-Based Paclitaxel with Solvent-Based
Paclitaxel Followed by Anthracyline/
Cyclophosphamide for Patients with Early Breast
Cancer (GeparSepto);GBG69
S3-02. NSABP B-36: A Randomized Phase III Trial
Comparing Six Cycle of 5-Fluorouracil (5-FU),
Epirubicin, and Cyclophosphamide (FEC) to Four Cycle
of Adriamycin and Cyclophoshamid (AC) in Patients
(pts) with Node-Negative Breast Cancer
S3-03. Ten Year Update of E119:phase III Study of
Doxorubicin-Cyclophosphamide Followed by Paclitaxel
or Docetaxel Given Every 3 weeks or Weekly in
Patients with Axillary Node-Positive or High-Risk
Node-Negative Breast Cancer
S3-04. The phase III ICE study: Adjuvant Ibandronate
with or without Capecitabine in Elderly Patients with
Moderate or High Risk Early Breast Cancer
Update on Transitional Research
10:10- 10:20
Coffee Break
10:20-11:10
Radiation Update
8:45-9:00
9:00- 9:15
9:15- 9:30
Dr. Sami Al Khatib
Dr. Mahmoud Shahin
Dr. Ahmed Al Shehri
Dr. Khalid Al Saleh
Dr. Alaa Kandil
Dr. Medhat Faris
Dr. Ahmed Awada
Dr. Mohamed Shabana
Dr. Abdulrahman Al Hadab
10:20- 10:35
S5-03.Accelerated Partial Breast Irradiation Using
Intensity Modulated Radiotherapy versus Whole
Breast Irradiation : 5 –Year Survival Results of a
Phase 3 Randomized Trial
Dr. Belal El Hawarri
10:35 – 11:10
New Insights in Beast Radiation
Dr. Fady Geara
11:10- 12:20
Surgical Update
11:10 – 11:25
S5-04. A Large Prospectively-Designed Study of the
DCIS Score: Predicting Recurrence Risk after Local
Excision for Ductal Carcinoma in Situ Patients with and
without Irradiation
Posters on Sential Node
Dr. Abdulaziz Al Saif
Delayed and Immediate Partial Breast Reconstruction
after Breast Conserving Surgery
Reconstruction for the High Risk Patient: Challenges of
Chemotherapy, Radiation Therapy and Selection
Dr. Jean-Yves Petit
11:25-11:40
11:40-12:00
12:00-12:20
Dr. Osama Al Malik
Dr. Manal Al Zaid
Dr. Khalid Al Hajri
Dr. Mahmoud Mohammed Al Masri
Dr. Mehra Golshan
12:30-1:30
Lunch Break
1:30-2:00
Supportive
1:30-1:45
S5-07. A Randomized, Open-Label, Multicenter, Phase Dr. Lobna Sedky Khalil
3 Study of Epoetin Alfa (EPO) Plus Standard Supportive
Care versus Standard Supportive Care in Anemic
Patients with Metastatic Breast Cancer (MBC)
Receiving Standard Chemotherapy
S5-08. Final Survival Analysis from the Randomized
Dr. Bassim Al Bahrani
Women’s Intervention Nutrition Study (WINS)
Evaluating Dietary Intervention as Adjuvant Breast
Cancer Therapy
1:45-2:00
Dr. Hesham El Ghazaly
Dr. Osama Al Hemsi
2:00-3:00
Case Discussion
3:00- 4:00
Closing Ceremony
Panelists:
- Dr. Alaa Kandil
- Dr. Ahmed Awada
- Dr. Heba El Zawahry
- Dr. Anees Hassan
Dr. Ahmed Faraj